

# Jonathan C Trent

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/559734/publications.pdf>

Version: 2024-02-01

194  
papers

9,074  
citations

41258

49  
h-index

45213

90  
g-index

196  
all docs

196  
docs citations

196  
times ranked

9417  
citing authors

#	ARTICLE	IF	CITATIONS
1	NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-1-S-41.	2.3	1,004
2	A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2004, 64, 5913-5919.	0.4	334
3	Molecular Subtypes of <i>KIT/PDGFR</i> Wild-Type Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2016, 2, 922.	3.4	291
4	Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 837-848.	5.1	262
5	Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for Survival. <i>Cancer Research</i> , 2007, 67, 2800-2808.	0.4	225
6	Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib. <i>Annals of Surgical Oncology</i> , 2006, 14, 14-24.	0.7	220
7	Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. <i>Cancer</i> , 2011, 117, 4939-4947.	2.0	212
8	Gastrointestinal Stromal Tumor: Role of CT in Diagnosis and in Response Evaluation and Surveillance after Treatment with Imatinib. <i>Radiographics</i> , 2006, 26, 481-495.	1.4	197
9	Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. <i>Modern Pathology</i> , 2009, 22, 1446-1456.	2.9	196
10	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	5.1	186
11	Angiosarcoma of the breast. <i>Cancer</i> , 2005, 104, 2682-2688.	2.0	183
12	Activity of dasatinib against <i>L576P KIT</i> mutant melanoma: Molecular, cellular, and clinical correlates. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2079-2085.	1.9	178
13	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. <i>Journal of Translational Medicine</i> , 2016, 14, 339.	1.8	167
14	A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. <i>Annals of Surgical Oncology</i> , 2009, 16, 910-919.	0.7	166
15	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 711-720.	3.7	161
16	An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. <i>Journal of Clinical Investigation</i> , 2007, 117, 4044-4054.	3.9	148
17	Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3414-3419.	3.3	144
18	Retroperitoneal soft tissue sarcoma: An analysis of radiation and surgical treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 158-163.	0.4	143

#	ARTICLE	IF	CITATIONS
19	Primary angiosarcomas of the breast. <i>Cancer</i> , 2007, 110, 173-178.	2.0	137
20	Outcomes and Cost of Outpatient or Inpatient Management of 712 Patients With Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2008, 26, 606-611.	0.8	136
21	Is there a role for surgery in patients with unresectable cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. <i>American Journal of Surgery</i> , 2003, 186, 665-669.	0.9	130
22	Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. , 2019, 7, 213.		118
23	A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. <i>Cancer</i> , 2003, 98, 2693-2699.	2.0	116
24	TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS. <i>Annual Review of Pharmacology and Toxicology</i> , 2005, 45, 357-384.	4.2	115
25	Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor. <i>JAMA Oncology</i> , 2018, 4, e184060.	3.4	112
26	Practical management of tyrosine kinase inhibitor-associated side effects in GIST. <i>Cancer Treatment Reviews</i> , 2011, 37, 75-88.	3.4	108
27	Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. <i>Cancer</i> , 2011, 117, 4925-4938.	2.0	104
28	Genetic aberrations in soft tissue leiomyosarcoma. <i>Cancer Letters</i> , 2009, 275, 1-8.	3.2	96
29	The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. <i>Clinical Sarcoma Research</i> , 2013, 3, 7.	2.3	96
30	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 550-560.	5.1	96
31	Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. <i>PLoS ONE</i> , 2015, 10, e0133813.	1.1	88
32	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1693-1701.	0.8	86
33	Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. <i>Cancer</i> , 2005, 103, 830-838.	2.0	81
34	Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes. <i>Journal of Clinical Oncology</i> , 2010, 28, e633-e636.	0.8	77
35	Genetic aberrations of gastrointestinal stromal tumors. <i>Cancer</i> , 2008, 113, 1532-1543.	2.0	72
36	Gastrointestinal Stromal Tumors: The GIST of Precision Medicine. <i>Trends in Cancer</i> , 2018, 4, 74-91.	3.8	71

#	ARTICLE	IF	CITATIONS
37	Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4015-4015.	0.8	71
38	Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. <i>International Journal of Cancer</i> , 2008, 122, 711-718.	2.3	70
39	Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma. <i>Cancer</i> , 2007, 110, 2293-2303.	2.0	69
40	Cardiac Tumors in a Tertiary Care Cancer Hospital: Clinical Features, Echocardiographic Findings, Treatment and Outcomes. <i>Heart International</i> , 2012, 7, hi.2012.e4.	0.4	69
41	Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. <i>Cancer</i> , 2010, 116, 184-192.	2.0	63
42	Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment. <i>Clinical Cancer Research</i> , 2011, 17, 7563-7573.	3.2	63
43	Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors. <i>Cancer</i> , 2006, 107, 2833-2841.	2.0	62
44	Single-Dose Palifermin Prevents Severe Oral Mucositis During Multicycle Chemotherapy in Patients With Cancer. <i>Annals of Internal Medicine</i> , 2010, 153, 358.	2.0	61
45	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	0.8	61
46	Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 15-24.	1.1	59
47	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 523-528.	0.8	58
48	Integrated Proteomics and Genomics Analysis Reveals a Novel Mesenchymal to Epithelial Reverting Transition in Leiomyosarcoma through Regulation of Slug. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2405-2413.	2.5	56
49	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	0.8	56
50	Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors. <i>International Journal of Cancer</i> , 2011, 129, 2533-2542.	2.3	55
51	Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2541-2546.	1.9	53
52	Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. <i>Cancer Medicine</i> , 2013, 2, 553-563.	1.3	51
53	Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. <i>Cancer Letters</i> , 2010, 291, 31-38.	3.2	49
54	Rhabdomyosarcoma in Adults: New Perspectives on Therapy. <i>Current Treatment Options in Oncology</i> , 2015, 16, 27.	1.3	48

#	ARTICLE	IF	CITATIONS
55	Desmoid fibromatosis: MRI features of response to systemic therapy. <i>Skeletal Radiology</i> , 2016, 45, 1365-1373.	1.2	46
56	PAX7 Expression in Rhabdomyosarcoma, Related Soft Tissue Tumors, and Small Round Blue Cell Neoplasms. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1305-1315.	2.1	43
57	The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. <i>Chinese Journal of Cancer</i> , 2012, 31, 327-334.	4.9	43
58	APEX1 Gene Amplification and Its Protein Overexpression in Osteosarcoma: Correlation with Recurrence, Metastasis, and Survival. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 161-169.	0.8	41
59	Resection of pulmonary metastases in pediatric patients with Ewing sarcoma improves survival. <i>Journal of Pediatric Surgery</i> , 2011, 46, 332-335.	0.8	41
60	Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. <i>Leukemia Research</i> , 2018, 64, 34-41.	0.4	41
61	Association of Intratumoral Vascular Endothelial Growth Factor Expression and Clinical Outcome for Patients with Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2007, 13, 6727-6734.	3.2	39
62	Exploiting antitumor immunity to overcome relapse and improve remission duration. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1113-1124.	2.0	39
63	New developments in gastrointestinal stromal tumor. <i>Current Opinion in Oncology</i> , 2006, 18, 386-395.	1.1	37
64	Expression of Bcl-2 in gastrointestinal stromal tumors. <i>Cancer</i> , 2006, 106, 1617-1623.	2.0	37
65	Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. <i>Cancer</i> , 2006, 107, 1898-1908.	2.0	37
66	R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis. <i>PLoS ONE</i> , 2011, 6, e26060.	1.1	35
67	Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. <i>Cancer</i> , 2011, 117, 380-389.	2.0	35
68	Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. <i>Modern Pathology</i> , 2008, 21, 826-836.	2.9	34
69	Midkine Enhances Soft-Tissue Sarcoma Growth: A Possible Novel Therapeutic Target. <i>Clinical Cancer Research</i> , 2008, 14, 5033-5042.	3.2	33
70	Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2014, 21, 2499-2505.	0.7	33
71	Results of a 2-arm Phase II study of 9-nitrocarnitine in patients with advanced soft-tissue sarcomas. <i>Cancer</i> , 2003, 97, 2848-2852.	2.0	31
72	Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 574-581.	0.6	30

#	ARTICLE	IF	CITATIONS
73	The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. <i>Cancer</i> , 2010, 116, 1847-1858.	2.0	30
74	Clinical Activity of Pazopanib in Metastatic Extrasosseous Ewing Sarcoma. <i>Rare Tumors</i> , 2015, 7, 86-88.	0.3	30
75	Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. <i>Cancer</i> , 2006, 107, 2237-2244.	2.0	29
76	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021, 26, e639-e649.	1.9	29
77	Neoadjuvant treatment of soft-tissue sarcoma: A multimodality approach. <i>Journal of Surgical Oncology</i> , 2010, 101, 327-333.	0.8	28
78	Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. <i>Molecular Oncology</i> , 2011, 5, 93-104.	2.1	27
79	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015, 20, 823-830.	1.9	26
80	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2016, 61, 94-101.	1.3	25
81	Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. <i>Cancers</i> , 2021, 13, 4816.	1.7	25
82	Sarcomatous Change After Sellar Irradiation in a Growth Hormone-Secreting Pituitary Adenoma. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, 378-383.	0.3	23
83	PAX3/FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 213-220.	1.2	23
84	Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the <scp>NCDB</scp> and <scp>SEER</scp>. <i>Cancer Medicine</i> , 2018, 7, 4228-4239.	1.3	23
85	Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments. <i>Current Opinion in Oncology</i> , 2010, 22, 330-335.	1.1	22
86	Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. <i>Clinical Sarcoma Research</i> , 2012, 2, 25.	2.3	22
87	Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2018, 103, 88-97.	1.3	22
88	Utility of Circulating Tumor DNA in the Management of Patients With GI Stromal Tumor: Analysis of 243 Patients. <i>JCO Precision Oncology</i> , 2020, 4, 66-73.	1.5	22
89	Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis. <i>Human Pathology</i> , 2014, 45, 1541-1545.	1.1	21
90	Ulcerative Keratitis in Gastrointestinal Stromal Tumor Patients Treated with Perifosine. <i>Ophthalmology</i> , 2008, 115, 483-487.	2.5	20

#	ARTICLE	IF	CITATIONS
91	Cutaneous and Subcutaneous Metastases of Gastrointestinal Stromal Tumors: A Series of 5 Cases With Molecular Analysis Cutaneous and Subcutaneous Metastases of Gastrointestinal Stromal Tumors : A Series of 5 Cases with Molecular Analysis.. American Journal of Dermatopathology, 2009, 31, 297-300.	0.3	20
92	Pazopanib in sarcomas. Current Opinion in Oncology, 2013, 25, 373-378.	1.1	20
93	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist, 2021, 26, e622-e631.	1.9	20
94	Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. Molecular Oncology, 2008, 2, 161-163.	2.1	19
95	Paraganglioma syndrome type 1 in a patient with Carneyâ€“Stratakis syndrome. Nature Reviews Endocrinology, 2010, 6, 110-115.	4.3	19
96	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAbâ€“004) in metastatic softâ€“tissue sarcomas. Cancer, 2019, 125, 2445-2454.	2.0	19
97	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. European Journal of Cancer, 2021, 155, 236-244.	1.3	19
98	Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors. Carcinogenesis, 2012, 33, 1674-1683.	1.3	18
99	Immunotherapy Strategies for Gastrointestinal Stromal Tumor. Cancers, 2021, 13, 3525.	1.7	18
100	Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors. Frontiers in Immunology, 2021, 12, 715727.	2.2	18
101	Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth. Cancers, 2020, 12, 141.	1.7	17
102	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patientsâ€“A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers, 2021, 13, 886.	1.7	17
103	The role of imatinib plasma level testing in gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology, 2011, 67, 45-50.	1.1	16
104	Low Frequency of Mutation Testing in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 270-278.	0.6	16
105	The immune system and gastrointestinal stromal tumor. Current Opinion in Oncology, 2015, 27, 338-342.	1.1	14
106	Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. Current Opinion in Oncology, 2010, 22, 336-341.	1.1	13
107	Small-Intestinal Rhabdoid Gastrointestinal Stromal Tumor (GIST). International Journal of Surgical Pathology, 2011, 19, 653-657.	0.4	13
108	The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e648-e655.	1.8	13



#	ARTICLE	IF	CITATIONS
109	Imatinib mesylate in the treatment of gastrointestinal stromal tumour. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 105-113.	0.9	12
110	Pharmacokinetics and Pharmacodynamics of Nilotinib in Gastrointestinal Stromal Tumors. <i>Seminars in Oncology</i> , 2011, 38, S28-S33.	0.8	12
111	Efficacy of Adjuvant and Neoadjuvant Therapies for Adult Orbital Sarcomas. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2010, 26, 185-189.	0.4	11
112	Characterization of 11 human sarcoma cell strains. <i>Cancer</i> , 2002, 95, 1569-1576.	2.0	10
113	Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. <i>Molecular Cancer</i> , 2009, 8, 99.	7.9	10
114	Oncogene regulation of endonuclease activation in apoptosis. <i>Cancer Letters</i> , 1995, 94, 9-16.	3.2	9
115	Managing GIST in the imatinib era: optimization of adjuvant therapy. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1445-1459.	1.1	9
116	An unusual site of metastasis from gastrointestinal stromal tumor. <i>Rare Tumors</i> , 2010, 2, 58.	0.3	9
117	Rapid evolution of the biology and treatment of sarcoma. <i>Current Opinion in Oncology</i> , 2008, 20, 393-394.	1.1	8
118	Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy. <i>BioDrugs</i> , 2017, 31, 379-392.	2.2	8
119	Progress in determining response to treatment in gastrointestinal stromal tumor. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 279-288.	1.1	8
120	Severity of COVID-19 in Cancer patients versus patients without Cancer: A Propensity Score Matching Analysis. <i>Journal of Cancer</i> , 2021, 12, 3558-3565.	1.2	8
121	A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11509-11509.	0.8	8
122	A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11547-11547.	0.8	8
123	The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	8
124	Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i> : A Multi-institutional Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 4092-4104.	3.2	8
125	Oxygen-17 and carbon-13 nuclear magnetic resonance spectra of thiophene- and pyrrole-2-carboxaldehyde condensation products prepared from ephedrine derivatives. <i>Journal of Heterocyclic Chemistry</i> , 1990, 27, 1853-1855.	1.4	7
126	Recent progress in the genomics of soft tissue sarcomas. <i>Current Opinion in Oncology</i> , 2008, 20, 395-399.	1.1	7



#	ARTICLE	IF	CITATIONS
127	An Integrated Study of Aberrant Gene Copy Number and Gene Expression in GIST and LMS. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 171-177.	0.8	7
128	Latest advances in adult gastrointestinal stromal tumors. <i>Future Oncology</i> , 2017, 13, 2183-2193.	1.1	7
129	MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis. <i>Radiology Imaging Cancer</i> , 2021, 3, e210016.	0.7	7
130	Identification of Genetic Alterations by Circulating Tumor DNA in Leiomyosarcoma: A Molecular Analysis of 73 Patients. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 64-68.	0.6	7
131	Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study. <i>Current Medical Research and Opinion</i> , 2012, 28, 805-814.	0.9	6
132	Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable. <i>Cancers</i> , 2021, 13, 3814.	1.7	6
133	Precision medicine in gastrointestinal stromal tumors. <i>Discovery Medicine</i> , 2019, 28, 267-276.	0.5	6
134	Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor. <i>Current Cancer Therapy Reviews</i> , 2005, 1, 93-108.	0.2	5
135	A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3209-3217.	3.2	5
136	CIC-rearranged round cell (Ewing-like) sarcoma of the uterus: Review of the literature. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100592.	0.3	5
137	Pathologic Response Rates after Neoadjuvant Therapy for Sarcoma: A Single Institution Study. <i>Cancers</i> , 2021, 13, 1074.	1.7	5
138	Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11512-11512.	0.8	5
139	What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 439-449.	1.3	5
140	The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 528-534.	0.6	4
141	Targeted Therapy of Sarcoma. , 2008, , 317-334.		4
142	IDH1 Mutation Induces HIF-1 $\alpha$ and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells. <i>Disease Markers</i> , 2022, 2022, 1-11.	0.6	4
143	Biomarkers in Gastrointestinal Stromal Tumor: Should We Equate Blood-Based Pharmacodynamics with Tumor Biology and Clinical Outcomes?. <i>Clinical Cancer Research</i> , 2007, 13, 2535-2536.	3.2	3
144	Extraskelatal Myxoid Chondrosarcoma with Small Bowel Metastasis Causing Bowel Obstruction. <i>Case Reports in Oncological Medicine</i> , 2012, 2012, 1-4.	0.2	3

#	ARTICLE	IF	CITATIONS
145	A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas. <i>Rare Tumors</i> , 2018, 10, 203636131878762.	0.3	3
146	How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers. <i>Current Medical Research and Opinion</i> , 2019, 35, 623-629.	0.9	3
147	Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: a report of two cases. <i>Gastrointestinal Stromal Tumor</i> , 0, 4, 1-1.	0.0	3
148	256â€¦Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors â€” case report from phase 2 study (NCT03104699)., 2020, 8, A279-A279.		3
149	Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)., 2019, , .		3
150	Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11511-11511.	0.8	3
151	EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma. <i>European Journal of Surgical Oncology</i> , 2021, , .	0.5	3
152	Mass spectra of thiophene- and pyrrole-2-carboxyaldehyde condensation products prepared from ephedrine derivatives. <i>Organic Mass Spectrometry</i> , 1989, 24, 1022-1024.	1.3	2
153	Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers â€” Letter. <i>Cancer Research</i> , 2011, 71, 2403-2403.	0.4	2
154	Use of Tyrosine Kinase Inhibitors in Patients With GI Stromal Tumor Who Are Pregnant or Considering Pregnancy: Driver Mutations and Circulating Tumor DNA. <i>Journal of Clinical Oncology</i> , 2018, 36, 2659-2660.	0.8	2
155	Multiomic analysis to reveal distinct molecular profiles of uterine and nonuterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11555-11555.	0.8	2
156	Deciphering the molecular landscape and the tumor microenvironment of perivascular epitheloid cell neoplasma (PEComa).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11539-11539.	0.8	2
157	Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11542-11542.	0.8	2
158	Metabolomic profiling of gastrointestinal stromal tumor (GIST) in human tissue samples and xenografts.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10516-10516.	0.8	2
159	Utility of circulating tumor DNA (ctDNA) in the management of patients with gastrointestinal stromal tumor (GIST): Analysis of 152 patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11539-11539.	0.8	2
160	Symptoms in gastrointestinal stromal tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9637-9637.	0.8	2
161	Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11541-11541.	0.8	2
162	Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor: Simultaneous Presentation. <i>Journal of Clinical Oncology</i> , 2007, 25, 4682-4683.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.. Journal of Clinical Oncology, 2021, 39, 11523-11523.	0.8	1
164	Abstract 1840: Metabolomic profiling of gastrointestinal stromal tumor (GIST) T1 cell lines in response to imatinib therapy. , 2015, , .		1
165	Genomic landscape of angiosarcoma: A targeted and immunotherapy biomarker analysis of 143 patients.. Journal of Clinical Oncology, 2020, 38, 11545-11545.	0.8	1
166	Frameshift mutations (Findel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.. Journal of Clinical Oncology, 2019, 37, 2617-2617.	0.8	1
167	Treatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report. JCO Precision Oncology, 2022, 6, e2100336.	1.5	1
168	Preface. Hematology/Oncology Clinics of North America, 2009, 23, xiii-xiv.	0.9	0
169	Reply to Adverse effects of imatinib-Dissecting heart from the rest. Cancer, 2011, 117, 228-229.	2.0	0
170	Metastatic/Recurrent Gastrointestinal Stromal Tumors: Does Surgical Resection Improve Survival?. Journal of the American College of Surgeons, 2015, 221, S142.	0.2	0
171	System Redesign of a Radiology Research Clinic for Oncology Clinical Trial Patients. Journal of the American College of Radiology, 2018, 15, 1304-1308.	0.9	0
172	Editor's Note: Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment. Clinical Cancer Research, 2019, 25, 3195-3195.	3.2	0
173	Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB).. Journal of Clinical Oncology, 2021, 39, 2599-2599.	0.8	0
174	Outcomes of metastatic synovial sarcoma with doxorubicin, pazopanib, and ifosfamide therapy.. Journal of Clinical Oncology, 2021, 39, e23552-e23552.	0.8	0
175	Differential risk factors between uterine sarcomas and malignant mixed Müllerian tumors.. Journal of Clinical Oncology, 2021, 39, e23551-e23551.	0.8	0
176	Abstract 2150: Genetic alterations in the major pathways in human osteosarcoma and their clinical significance. , 2010, , .		0
177	Abstract 618: Anti-tumor effects of Notch pathway activation in Gastrointestinal Stromal Tumors cells. , 2011, , .		0
178	Abstract 3239: The Notch pathway as a new target in gastrointestinal stromal tumors. , 2012, , .		0
179	An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. Journal of Clinical Investigation, 2013, 123, 4980-4980.	3.9	0
180	A phase I/II study of sunitinib in young patients with advanced gastrointestinal stromal tumor.. Journal of Clinical Oncology, 2014, 32, TPS10601-TPS10601.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Panobinostat and carfilzomib cytotoxicity in IDH-mutant human chondrosarcoma.. Journal of Clinical Oncology, 2016, 34, 11027-11027.	0.8	0
182	Inhibition of autophagy sensitizes gastrointestinal stromal tumor cells to TKI/Bcl-2 inhibitors-induced apoptosis.. Journal of Clinical Oncology, 2017, 35, 11036-11036.	0.8	0
183	Factors impacting contemporary management of high-grade extremity sarcoma: An analysis of 12,020 patients.. Journal of Clinical Oncology, 2017, 35, 11017-11017.	0.8	0
184	A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas.. Journal of Clinical Oncology, 2017, 35, e22521-e22521.	0.8	0
185	Abstract 4292: Indole-3-carbinol (I3C) enhances efficacy of Gemcitabine in leiomyosarcoma. , 2017, , .		0
186	Survival of patients treated by a Precision Oncology approach is determined by performance status and lines of therapy.. Journal of Clinical Oncology, 2018, 36, 12071-12071.	0.8	0
187	Increasing access to NGS tests for women and racial minorities to lift barriers to molecular driven clinical trial enrollment.. Journal of Clinical Oncology, 2018, 36, 6561-6561.	0.8	0
188	Safety and efficacy of irreversible electroporation for aggressive fibromatosis: Initial experience.. Journal of Clinical Oncology, 2018, 36, e23549-e23549.	0.8	0
189	Successful automated normalization of cancer outcomes for half a million patients across four disparate health systems.. Journal of Clinical Oncology, 2018, 36, e18763-e18763.	0.8	0
190	Evolution of precision oncology treatment options over time.. Journal of Clinical Oncology, 2018, 36, e24179-e24179.	0.8	0
191	Abstract 864: Mutant IDH1 is essential for chondrosarcoma growth. , 2019, , .		0
192	Abstract CT058: Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs). , 2019, , .		0
193	Clinical behavior and treatment outcomes in angiosarcoma: A 10-year retrospective review.. Journal of Clinical Oncology, 2020, 38, e23555-e23555.	0.8	0
194	Oncological Outcomes in Patients with Appendicular Myxofibrosarcomas: A Retrospective Study. Journal of Oncology, 2021, 2021, 1-8.	0.6	0